Andrew George Popplewell

USPTO Granted Patents = 35 (Patent Applications = 11)

CIPO Patents = 8 (Patent Applications = 1)

EPO Patents = 17 (Patent Applications = 8)

Average Co-Inventor Count = 4.0

ph-index = 11

Forward Citations = 348(Granted Patents)

Location History:

Middlesex, GB (2009 - 2014)
Staines, GB (2006 - 2016)
Berkshire, GB (2008 - 2018)
Slough, GB (2007 - 2019)

Company Filing History:

Wyeth Holdings Corporation

Celltech Chiroscience Limited

where one patent can have more than one assignee

Years Active: 2006-2019

Loading Chart...

35 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10308723 - Method of treating inflammation by administering antibody molecules which bind IL-17A and IL-17F (2019-06-04),

2. 10017575 - Antibody molecules having specificity for human OX40 (2018-07-10),

3. 9890219 - Methods of treating an IL-17A mediated pathological condition (2018-02-13),

4. 9631015 - Methods for treating IL-6 mediated diseases with antibody molecules specific for IL-6 (2017-04-25),

5. 9428570 - Antibody molecules having specificity for human OX40 (2016-08-30),

6. 9351986 - Calicheamicin derivative-carrier conjugates (2016-05-31),

7. 9321840 - Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof (2016-04-26),

8. 9249232 - Framework selection (2016-02-02),

9. 9096668 - Methods for making antibody molecules having specificity for human IL-6 (2015-08-04),

10. 8865167 - Neutralising antibody molecules having specificity for human IL-17 (2014-10-21),

11. 8835611 - Calicheamicin derivative-carrier conjugates (2014-09-16),

12. 8784823 - Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind CD154 and uses thereof (2014-07-22),

13. 8747857 - Calicheamicin derivative-carrier conjugates (2014-06-10),

14. 8617847 - Nucleic acids encoding antibody molecules which bind IL-17A and IL-17F (2013-12-31),

15. 8614295 - Antibody molecules having specificity for human OX40 (2013-12-24),

Title: Andrew George Popplewell: Innovator in Antibody Therapeutics

Introduction: Andrew George Popplewell, based in Slough, GB, is a distinguished inventor known for his significant contributions to the field of antibody therapeutics. With a remarkable portfolio comprising 35 patents, his work has focused on innovative approaches to treat inflammation and other illnesses through targeted antibody molecules.

Latest Patents: Popplewell's latest patents reflect his pioneering research in therapeutic antibodies. One of his noteworthy patents is the "Method of treating inflammation by administering antibody molecules which bind IL-17A and IL-17F." This invention centers on antibody molecules specifically targeting both IL-17A and IL-17F, alongside their therapeutic uses and methods of production. Another significant patent includes "Antibody molecules having specificity for human OX40," which delineates the therapeutic applications of antibodies that target antigenic determinants of human OX40, along with production methodologies.

Career Highlights: Throughout his career, Andrew George Popplewell has made substantial strides in biopharmaceutical research. His tenure at UCB Pharma and UCB Biopharma Sprl has enabled him to lead innovative projects that have advanced the understanding and treatment of various diseases through biotherapeutics.

Collaborations: Among his notable colleagues, Ralph Adams and Stephen Edward Rapecki have played pivotal roles in advancing Popplewell's research initiatives. Their collaboration has fostered a synergistic environment, propelling ground-breaking work in antibody development.

Conclusion: Andrew George Popplewell stands out as an influential figure in the realm of innovations related to antibody therapeutics. His extensive patent portfolio and collaborative efforts signify a commitment to improving healthcare through scientific advancements, making him a notable inventor in the biomedical sphere.

This text is generated by artificial intelligence and may not be accurate.